2Reveille JD. Antibodies to centromere and centriole in scleroderma spectrum disorders. J Clin Invest, 1992, 89: 1208-1213. 被引量：1
3Hu PQ, Fertig N, Medsger TA Jr. Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol, 2004, 173: 2834. 被引量：1
4Hall HI, Jamison P, Fulton JP. Reporting cutaneous melanoma to cancer registries in the United States. J Am Acad Dermatol, 2003,49: 624-630. 被引量：1
5Lakos G, Takagawa S, Chen SJ, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of seleroderma. Am J Pathol, 2004, 165: 203-217. 被引量：1
6Hasegawa M, Sato S, Takehara K. Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. ArchDermatol Res, 2004,296:89-93. 被引量：1
7Takeuchi F, Nabeta H, Fussel M, et al. Association of the TNF-α13 microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis, 2000, 59: 293-296. 被引量：1
8Hamilton RF Jr, Parsley E, Holian A. Alveolar maerophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes. Am J Physiol Lung Cell Mol Physiol, 2004, 286:1202-1209. 被引量：1
9Jun JB, Kuechle M, Harlan JM, et al. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol, 2003,15:756-760. 被引量：1
10Yamamoto T, Kuroda M, Nishioka K. Animal model of sclerotic skin Ⅲ: histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res, 2000, 292:535-541. 被引量：1
